2022
DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Doyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChildDiabetic KetoacidosisGlycated HemoglobinHumansInsulinInsulin Infusion SystemsRetrospective StudiesConceptsContinuous glucose monitorHigher A1C levelsA1c levelsDKA eventsInsulin pumpPump usersPump-treated patientsRetrospective chart reviewPediatric endocrinology practiceType 1 diabetesInsulin pump usersConcurrent illnessDKA preventionPump patientsDiabetes durationDKA episodesMean A1CChart reviewEndocrinology practiceDKA ratesDKA severityMean ageInsulin omissionMost episodesPatientsAssessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdults
2021
Youth and parent preferences for an ideal AP system: It is all about reducing burden
Commissariat PV, Roethke LC, Finnegan JL, Guo Z, Volkening LK, Butler DA, Dassau E, Weinzimer SA, Laffel LM. Youth and parent preferences for an ideal AP system: It is all about reducing burden. Pediatric Diabetes 2021, 22: 1063-1070. PMID: 34324772, PMCID: PMC8530854, DOI: 10.1111/pedi.13252.Peer-Reviewed Original Research
2020
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, Schoelwer M, Ruedy KJ, Jost E, Carria L, Emory E, Hsu LJ, Oliveri M, Kollman CC, Dokken BB, Weinzimer SA, DeBoer MD, Buckingham BA, Cherñavvsky D, Wadwa RP. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. New England Journal Of Medicine 2020, 383: 836-845. PMID: 32846062, PMCID: PMC7920146, DOI: 10.1056/nejmoa2004736.Peer-Reviewed Original ResearchConceptsType 1 diabetesSensor-augmented insulin pumpClosed-loop groupGlucose levelsMedian percentageTarget rangeInsulin pumpInsulin deliveryParallel-group trialYears of ageContinuous glucose monitoringDiabetic ketoacidosisPrimary outcomeSevere hypoglycemiaHemoglobin levelsRandomized trialsGlycemic outcomesPercentage of timeChildren 6Control groupType 1DiabetesMean percentageGlucose monitoringTrials
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdultsClinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019, 42: 1593-1603. PMID: 31177185, PMCID: PMC6973648, DOI: 10.2337/dci19-0028.Peer-Reviewed Original Research
2017
International Consensus on Use of Continuous Glucose Monitoring
Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017, 40: 1631-1640. PMID: 29162583, PMCID: PMC6467165, DOI: 10.2337/dc17-1600.Peer-Reviewed Original ResearchStandardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, Kowalski AJ, Madden P, McAuliffe-Fogarty AH, McElwee-Malloy M, Peters A, Raman S, Reifschneider K, Rubin K, Weinzimer SA. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017, 40: 1622-1630. PMID: 29162582, PMCID: PMC5864122, DOI: 10.2337/dc17-1624.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesType 1 diabetesAmerican Diabetes AssociationPediatric Endocrine SocietyDiabetic ketoacidosisEndocrine SocietyClinical EndocrinologistsPriority outcomesDiabetes AssociationT1D ExchangeHarry B. Helmsley Charitable TrustDiabetes educatorsLong-term clinical impactType 1American AssociationType 2 diabetesSteering CommitteeLeona M.Helmsley Charitable TrustMeaningful outcome measuresType 1 diabetes outcomesAdvisory CommitteeGlucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2016
Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report
Maahs DM, Buckingham BA, Castle JR, Cinar A, Damiano ER, Dassau E, DeVries JH, Doyle FJ, Griffen SC, Haidar A, Heinemann L, Hovorka R, Jones TW, Kollman C, Kovatchev B, Levy BL, Nimri R, O’Neal D, Philip M, Renard E, Russell SJ, Weinzimer SA, Zisser H, Lum JW. Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care 2016, 39: 1175-1179. PMID: 27330126, PMCID: PMC4915553, DOI: 10.2337/dc15-2716.Peer-Reviewed Original ResearchMeSH KeywordsBlood GlucoseClinical Trials as TopicConsensusDiabetes Mellitus, Type 1Glycated HemoglobinHumansOutcome Assessment, Health CarePancreas, Artificial
2014
Alterations in White Matter Structure in Young Children With Type 1 Diabetes
Barnea-Goraly N, Raman M, Mazaika P, Marzelli M, Hershey T, Weinzimer SA, Aye T, Buckingham B, Mauras N, White NH, Fox LA, Tansey M, Beck RW, Ruedy KJ, Kollman C, Cheng P, Reiss AL, . Alterations in White Matter Structure in Young Children With Type 1 Diabetes. Diabetes Care 2014, 37: 332-340. PMID: 24319123, PMCID: PMC3898758, DOI: 10.2337/dc13-1388.Peer-Reviewed Original Research
2013
Effectiveness of a Spanish Language Clinic for Hispanic Youth with Type 1 Diabetes
Palau-Collazo MM, Rose P, Sikes K, Kim G, Benavides V, Urban A, Weinzimer S, Tamborlane W. Effectiveness of a Spanish Language Clinic for Hispanic Youth with Type 1 Diabetes. Endocrine Practice 2013, 19: 800-804. PMID: 23757616, DOI: 10.4158/ep13004.or.Peer-Reviewed Original ResearchMeSH KeywordsChildCommunication BarriersDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHispanic or LatinoHumansLanguageMalePhysician-Patient RelationsConceptsBody mass indexMean baseline glycated hemoglobin levelBaseline glycated hemoglobin levelHispanic pediatric patientsTarget HbA1c levelDuration of diabetesGlycated hemoglobin levelsType 1 diabetesHbA1c levelsPediatric patientsHemoglobin levelsHispanic patientsMass indexPatientsMetabolic controlType 1Pilot studyClinicDiabetesT1DLanguage clinicPreliminary findingsHispanic familiesHispanic youthGroup
2009
Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes
Tsalikian E, Tamborlane W, Xing D, Becker D, Mauras N, Fiallo-Scharer R, Buckingham B, Weinzimer S, Steffes M, Singh R, Beck R, Ruedy K, Kollman C. Blunted Counterregulatory Hormone Responses to Hypoglycemia in Young Children and Adolescents With Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1954-1959. PMID: 19675205, PMCID: PMC2768200, DOI: 10.2337/dc08-2298.Peer-Reviewed Original ResearchConceptsType 1 diabetesPlasma glucose concentrationEpinephrine responsePlasma glucoseYoung childrenInsulin pump-treated patientsHypoglycemia-associated autonomic failurePump-treated patientsLower plasma glucose concentrationsIntensive insulin therapySymptoms of hypoglycemiaInsulin infusion protocolCounterregulatory hormone concentrationsGlucose concentrationAbsence of signsClosed-loop insulin delivery systemsContinuous glucose monitoringAcute complicationsAutonomic failureCounterregulatory hormonesSympathoadrenal responseInsulin therapyPatient ageNondiabetic adolescentsSymptom scoresSustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
Bode B, Beck R, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy K, Tamborlane W, Weinzimer S, Wolpert H. Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2009, 32: 2047-2049. PMID: 19675193, PMCID: PMC2768224, DOI: 10.2337/dc09-0846.Peer-Reviewed Original Research
2008
Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes
Tamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Hirsch I, Huang E, Kollman C, Kowalski A, Laffel L, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal Of Medicine 2008, 359: 1464-1476. PMID: 18779236, DOI: 10.1056/nejmoa0805017.Peer-Reviewed Original ResearchConceptsYears of ageContinuous glucose monitoringContinuous monitoring groupPatients 25 yearsGlycated hemoglobin levelsType 1 diabetesHemoglobin levelsGlucose monitoringStudy groupControl groupType 1 diabetes mellitusMulticenter clinical trialBetween-group differencesHemoglobin outcomesYounger patientsDiabetes mellitusGlycemic controlIntensive therapyPrimary outcomeSevere hypoglycemiaClinical trialsIntensive treatmentAge groupsBlood glucose metersType 1
2007
Continuous Glucose Monitoring in Children with Type 1 Diabetes
Buckingham B, Beck R, Tamborlane W, Xing D, Kollman C, Fiallo-Scharer R, Mauras N, Ruedy K, Tansey M, Weinzimer S, Wysocki T. Continuous Glucose Monitoring in Children with Type 1 Diabetes. The Journal Of Pediatrics 2007, 151: 388-393.e2. PMID: 17889075, PMCID: PMC2045068, DOI: 10.1016/j.jpeds.2007.03.047.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringContinuous glucose monitorReal-time continuous glucose monitoringGlucose monitoringMean hemoglobin A1cSevere skin reactionsType 1 diabetesGlucose monitorContinuous glucose monitoring systemInsulin pump usersDaily useGlycemic controlHemoglobin A1cDaily treatmentGlucose monitoring systemSkin reactionsWeek 9Glucose valuesBaseline levelsType 1WeeksPump usersT1DHigh satisfactionChildren